Analysis reveals rise in claim denial rates for cancer-related advanced genetic testing

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national coverage determination that established coverage standards for NGS testing.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup